Diagnostic accuracy of 2D-SWE ultrasound for liver fibrosis assessment in MASLD: A multi-level random effects model meta-analysis

IF 12.9 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Hepatology Pub Date : 2024-12-17 DOI:10.1097/hep.0000000000001190
Madalina-Gabriela Taru, Dan-Corneliu Leucuta, Monica Lupsor-Platon, Laura Turco, Silvia Ferri, Ahmed Hashim, Olga Hilda Orasan, Bogdan Procopet, Horia Stefanescu, Maria Cristina Morelli, Fabio Piscaglia, Federico Ravaioli
{"title":"Diagnostic accuracy of 2D-SWE ultrasound for liver fibrosis assessment in MASLD: A multi-level random effects model meta-analysis","authors":"Madalina-Gabriela Taru, Dan-Corneliu Leucuta, Monica Lupsor-Platon, Laura Turco, Silvia Ferri, Ahmed Hashim, Olga Hilda Orasan, Bogdan Procopet, Horia Stefanescu, Maria Cristina Morelli, Fabio Piscaglia, Federico Ravaioli","doi":"10.1097/hep.0000000000001190","DOIUrl":null,"url":null,"abstract":"Background &amp; Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) imposes significant healthcare burdens. Early detection of advanced fibrosis and cirrhosis in MASLD is essential due to their unfavourable outcomes. This multi-level random-effects meta-analysis aimed to provide the best evidence for the diagnostic accuracy of two-dimensional shear wave elastography (2D-SWE) in detecting liver fibrosis in biopsy-proven MASLD. Approach &amp; Results: Systematic search in PubMed/MEDLINE, Embase, Scopus, Web of Science, LILACS, and Cochrane Library electronic databases for full-text articles published in any language up to the 26<jats:sup>th</jats:sup> of February 2024. Included studies reported liver stiffness measurement (LSM) by 2D-SWE and used histological diagnosis as gold standard. A linear mixed-effects multiple thresholds model was employed, and summary estimates for sensitivity (Se), specificity (Sp), and summary area under the curve (sAUC) were computed. 20 observational studies (SuperSonic Imagine, General Electric Healthcare, Canon Medical Systems) fulfilled the inclusion criteria, comprising 2223 participants with biopsy-proven MASLD. The prevalence of mild fibrosis (F1), significant fibrosis (F2), advanced fibrosis (F3), and cirrhosis (F4) was 30.0%, 18.5%, 17.9%, and 10.9%, respectively. The sAUCs [95%CI] in detecting ≥F1, ≥F2, ≥F3, and F4 for all ultrasound machines considered together were 0.82 [0.16-0.98], 0.82 [0.76-0.88], 0.86 [0.77-0.93], and 0.89 [0.80-0.95], respectively. The optimal cut-off values were 6.432 kPa for ≥F1, 8.174 kPa for ≥F2, 9.418 kPa for ≥F3, and 11.548 kPa for F4, respectively. Conclusions: Our meta-analysis identified optimised cut-offs for fibrosis staging by 2D-SWE in etiology-specific chronic liver diseases (MASLD), with excellent diagnostic performance, underscoring the potential for standardising cut-off values.","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"23 1","pages":""},"PeriodicalIF":12.9000,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/hep.0000000000001190","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background & Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) imposes significant healthcare burdens. Early detection of advanced fibrosis and cirrhosis in MASLD is essential due to their unfavourable outcomes. This multi-level random-effects meta-analysis aimed to provide the best evidence for the diagnostic accuracy of two-dimensional shear wave elastography (2D-SWE) in detecting liver fibrosis in biopsy-proven MASLD. Approach & Results: Systematic search in PubMed/MEDLINE, Embase, Scopus, Web of Science, LILACS, and Cochrane Library electronic databases for full-text articles published in any language up to the 26th of February 2024. Included studies reported liver stiffness measurement (LSM) by 2D-SWE and used histological diagnosis as gold standard. A linear mixed-effects multiple thresholds model was employed, and summary estimates for sensitivity (Se), specificity (Sp), and summary area under the curve (sAUC) were computed. 20 observational studies (SuperSonic Imagine, General Electric Healthcare, Canon Medical Systems) fulfilled the inclusion criteria, comprising 2223 participants with biopsy-proven MASLD. The prevalence of mild fibrosis (F1), significant fibrosis (F2), advanced fibrosis (F3), and cirrhosis (F4) was 30.0%, 18.5%, 17.9%, and 10.9%, respectively. The sAUCs [95%CI] in detecting ≥F1, ≥F2, ≥F3, and F4 for all ultrasound machines considered together were 0.82 [0.16-0.98], 0.82 [0.76-0.88], 0.86 [0.77-0.93], and 0.89 [0.80-0.95], respectively. The optimal cut-off values were 6.432 kPa for ≥F1, 8.174 kPa for ≥F2, 9.418 kPa for ≥F3, and 11.548 kPa for F4, respectively. Conclusions: Our meta-analysis identified optimised cut-offs for fibrosis staging by 2D-SWE in etiology-specific chronic liver diseases (MASLD), with excellent diagnostic performance, underscoring the potential for standardising cut-off values.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
背景& 目的:代谢功能障碍相关性脂肪性肝病(MASLD)给医疗保健带来了巨大负担。由于晚期肝纤维化和肝硬化对患者的预后不利,因此必须及早发现。这项多层次随机效应荟萃分析旨在为二维剪切波弹性成像(2D-SWE)检测活检证实的MASLD肝纤维化的诊断准确性提供最佳证据。方法与amp; 结果:系统检索 PubMed/MEDLINE、Embase、Scopus、Web of Science、LILACS 和 Cochrane Library 电子数据库中截至 2024 年 2 月 26 日以任何语言发表的全文文章。纳入的研究报告采用二维-SWE测量肝脏硬度(LSM),并将组织学诊断作为金标准。研究采用了线性混合效应多阈值模型,并计算了灵敏度(Se)、特异度(Sp)和曲线下面积(sAUC)的汇总估计值。20 项观察性研究(SuperSonic Imagine、通用电气医疗保健公司、佳能医疗系统公司)符合纳入标准,包括 2223 名经活检证实的 MASLD 患者。轻度纤维化(F1)、重度纤维化(F2)、晚期纤维化(F3)和肝硬化(F4)的发生率分别为 30.0%、18.5%、17.9% 和 10.9%。所有超声设备检测≥F1、≥F2、≥F3 和 F4 的 sAUCs [95%CI] 分别为 0.82 [0.16-0.98]、0.82 [0.76-0.88]、0.86 [0.77-0.93] 和 0.89 [0.80-0.95]。≥F1、≥F2、≥F3 和 F4 的最佳临界值分别为 6.432 kPa、8.174 kPa、9.418 kPa 和 11.548 kPa。结论我们的荟萃分析为病因特异性慢性肝病(MASLD)的二维-SWE纤维化分期确定了最佳的临界值,诊断效果极佳,凸显了临界值标准化的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Hepatology
Hepatology 医学-胃肠肝病学
CiteScore
27.50
自引率
3.70%
发文量
609
审稿时长
1 months
期刊介绍: HEPATOLOGY is recognized as the leading publication in the field of liver disease. It features original, peer-reviewed articles covering various aspects of liver structure, function, and disease. The journal's distinguished Editorial Board carefully selects the best articles each month, focusing on topics including immunology, chronic hepatitis, viral hepatitis, cirrhosis, genetic and metabolic liver diseases, liver cancer, and drug metabolism.
期刊最新文献
Cell metabolism-based therapy for liver fibrosis, repair, and hepatocellular carcinoma. Controversies regarding albumin therapy in cirrhosis. A genetic basis of mitochondrial DNAJA3 in nonalcoholic steatohepatitis-related hepatocellular carcinoma. FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1. Alternatives to animal testing to assess MASH drugs and hepatotoxicity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1